Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



(I)

wherein:

R_3 is a monocycle selected from the group consisting of C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

R_4 is a moiety selected from the group consisting of C_2-C_{14} alkyl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein R_4 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

R_5' and R_5" are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxyl, acyl, amide, amino, acetamido and nitro;

R_6 is a group selected from the following formulae:

wherein:

R_8 is hydrogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxyl;

$R_{8'}$ is an C_3-C_{14} alkyl, 2 to 9 membered heteroalkyl, acyl, C_1-C_3 alkyl-nitrile, C_1-C_3 alkyl-carboxamide, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form an unsubstituted or substituted C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

 , or  , and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_9 is hydrogen, or a moiety selected from the group consisting of an C_1-C_9 alkyl, C_2-C_9 alkenyl, 2-9 membered heteroalkenyl, C_1C_9 alkylamide, C_1-C_9 alkyl-carboxamide, 2-9 membered heteroalkyl, C_1-C_4 alkyl-cycloalkyl, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not

 , and wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1-C_6 alkoxyl, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j$(C_1-C_6 alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxyl, and trifluoromethoxy, R_b and R_c are independently selected from H, C_1-C_6 alkyl, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$ (4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C_1-C_6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$,

$-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR_dR_e)_t(C_3$-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO_2 group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C_1-C_4 alkyl, C_1-C_4 alkoxyl and $-NR_dR_e$ wherein R_d and R_e are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer~~, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt~~ thereof.

2. (Currently Amended) A compound of Formula (II):



(II)

wherein:

R_4 is a moiety selected from the group consisting of C_2-C_{14} alkyl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein R_4 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

R_5' and R_5" are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxyl, acyl, amide, amino, acetamido and nitro;

R_6 is a group selected from the following formulae:



wherein:

R_8 is hydrogen, C_{1-3} alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxyl;

$R_{8'}$ is an C_3-C_{14} alkyl, 2-9 membered heteroalkyl, acyl, C_1-C_3 alkyl-nitrile, C_1-C_3 alkyl-carboxamide, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with

R_8 cyclizes to form a C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not



and wherein R_8, is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_9 is hydrogen, or a moiety selected from the group consisting of an C_1-C_9 alkyl, C_2-C_9 alkenyl, 2-9 membered heteroalkenyl, C_1-C_9 alkylamide, C_1-C_9 alkyl-carboxamide, 2-9 membered heteroalkyl, C_1-C_4 alkyl-cycloalkyl, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not



, wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1-C_6 alkoxyl, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j$(C_1-C_6 alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxyl, and trifluoromethoxy, R_b and R_c are independently selected from H, C_1-C_6 alkyl, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C1-C6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with an oxo (=O)

moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$, $-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR_dR_e)_t(C_3$-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl);

wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO_2 group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NR_dR_e$ wherein R_d and R_e are as defined above;

and wherein Ph means phenyl;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, ~~prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt~~ thereof.

3. (Currently Amended) A compound according to Claim 1 wherein R_4 is a phenyl;

R_3 is a monocycle selected from the group consisting of C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

R_5' and R_5" are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxyl, acyl, amide, amino, acetamido and nitro;

R_6 is a group selected from the following formulae:



wherein:

R_8 is hydrogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxyl;

$R_{8'}$ is an C_{3-14} alkyl, 2-9 membered heteroalkyl, acyl, C_{1-3} alkyl-nitrile, C_{1-3} alkyl-carboxamide, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form a C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

 , or  , and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_9 is hydrogen, or a moiety selected from the group consisting of an C_{1-9} alkyl, C_{2-9} alkenyl, 2-9 membered heteroalkenyl, C_{1-9} alkylamide, C_{1-9} alkyl-carboxamide, 2-9 membered heteroalkyl, C_{1-4} alkyl-cycloalkyl, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not

 ,

wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1-C_6 alkoxyl, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$-C_6 alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t(C_3$-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_tO(CR_dR_e)_q(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxyl, and trifluoromethoxy, R_b and R_c are independently selected from H, C_1-C_6 alkyl, $-(CR_dR_e)_t(C_3$-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C_1-C_6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$,

-C(O)OR_b, -$NR_bC(O)R_c$, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), -$(CR_dR_e)_t$(aryl), -$(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and –$(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO_2 group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and –NR_dR_e wherein R_d and R_e are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer~~, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt~~ thereof.

4. (Currently Amended) A compound of Formula (IV):



wherein:

R_3 is a monocycle selected from the group consisting of C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

R_4 is a moiety selected from the group consisting of substituted or unsubstituted C_2-C_{14} alkyl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

R_5' and R_5" are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxyl, acyl, amide, amino, acetamido and nitro;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

R_8 is hydrogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxyl;

$R_{8'}$ is an C_{3-14} alkyl, 2-9 membered heteroalkyl, acyl, C_{1-3} alkyl-nitrile, C_{1-3} alkyl-carboxamide, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form a C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

 , or  , and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_9 is hydrogen, or a moiety selected from the group consisting of an C_{1-9} alkyl, C_{2-9} alkenyl, 2-9 membered heteroalkenyl, C_{1-9} alkylamide, C_{1-9} alkyl-carboxamide, 2-9 membered heteroalkyl, C_{1-4} alkyl-cycloalkyl, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not

 ,

wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxyl, acyl, amide and nitro;

wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1-C_6 alkoxyl, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j$(C_1-C_6 alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxyl, and trifluoromethoxy, R_b and R_c are independently selected from H, C_1-C_6 alkyl, $-(CR_dR_e)_t$(C_3-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C_1-C_6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$,

$-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR_dR_e)_t(C_3$-C_{10} cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO_2 group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NR_dR_e$ wherein R_d and R_e are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer~~, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt~~ thereof.

5. (Currently Amended) A compound according to Claim 1 having the structure:







and multimers~~, pharmaceutically acceptable salts, prodrugs, and active metabolites~~ thereof.

6. (Currently Amended) A pharmaceutical composition comprising an effective amount of an agent to inhibit cellular proliferation and a pharmaceutically acceptable carrier, said agent being selected from the group consisting of compounds~~,~~ and multimers~~, pharmaceutically acceptable salts, prodrugs, and active metabolites~~ as defined in any of claims 1, 2, 3, and 4.

7. (Withdrawn) A method of inhibiting a CDK selected from CDK2, CDK4, CDK6 or CDK complex, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3, and 4.

8. (Withdrawn) A method of treating cellular proliferative diseases, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3 and 4.

9. (Withdrawn) A method according to claim 8, wherein the disease is cancer, autoimmune disease, viral disease, fungal disease, neurodegenerative disorder or cardiovascular disease.